Article Text

Download PDFPDF
Systematic review and meta-analysis
Medical management strategies to prevent recurrent nephrolithiasis are stagnant and stronger evidence is needed to reduce morbidity
  1. Yair Lotan
  1. Department of Urology, Southwestern Medical Center, University of Texas, Dallas, Texas, USA
  1. Correspondence to : Dr Yair Lotan, Department of Urology, Southwestern Medical Center, University of Texas, 5323 Harry Hines Blvd, J8.112, Dallas, TX, USA; yair.lotan{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMedWeb of Science


The management of urolithiasis represents a common and costly problem for healthcare services. Up to 15% of the general population may be affected at some point in their lives and 25–50% of cases will recur.1 ,2 While minimally invasive surgical treatments can treat most of the upper tract calculi, acute stone events and surgical treatment persist as a significant source of morbidity for patients with recurrent urolithiasis. Consequently, the prevention of stone recurrence is an appealing strategy. Although the benefit of dietary modification in preventing stone formation has long been recognised,3 drug treatments have been shown to provide additional protection beyond that of dietary measures alone.4 The goal …

View Full Text


  • Competing interests None.